Full Press Release Details
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD)
PRIMA SECURES JAPANESE
PATENT GRANT FOR IMP731 ANTIBODY
SYDNEY, AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company )
announces the grant of Japanese patent no. 6177735 entitled Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease by the Japanese Patent Office.
The patent was filed as a divisional application and is directed to Prima s IMP731 antibody that was originally developed by Immutep SA, now a wholly
owned subsidiary of Prima. The granted claims provide broad protection for the antibody and also use of the antibody in the manufacture of a medicament for treating or preventing organ transplant rejection or treating an autoimmune disease. The
patent expiry date is 30 April 2028.
Rights for the development of the IMP731 antibody were granted in December 2010 to GSK who have commenced
first-in-human clinical trials of a proprietary antibody (GSK2831781) derived from IMP731.
About IMP731 and GSK2831781
IMP731 and GSK2831781 are designed to specifically deplete potentially pathogenic, recently activated, LAG-3 expressing T cells which are enriched at the
disease site in T-cell driven immuno-inflammatory disorders and should spare other T-cells which may be necessary for other functions.
the 2010 agreement between Immutep and GSK, GSK has responsibility for all development costs for GSK2831781. Under the agreement, Prima is entitled to receive payments and milestones totalling up to 64 million and single-digit, tiered
royalties if all objectives are achieved.
A Phase 1, first-in-human clinical study of GSK2831781 for the treatment of autoimmune diseases has commenced
and further information may be obtained at https://clinicaltrials.gov/ct2/show/NCT02195349.
Prima BioMed is a globally active biotechnology company that is a leader in the development of immunotherapeutic products. Prima BioMed is dedicated to
leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.
Prima s current lead product is IMP321, based on the LAG-3 immune control mechanism which plays a vital role
in the regulation of the T cell immune response. IMP321, which is a soluble LAG-3Ig fusion protein, is an APC activator boosting T cell responses. IMP321 is currently in a Phase II clinical trial as a chemoimmunotherapy for metastatic breast cancer
termed AIPAC (clinicaltrials.gov identifier NCT 02614833) and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier NCT 02676869). A number of additional LAG-3 products including
antibodies for immune response modulation in autoimmunity and cancer are being developed by Prima s pharmaceutical partners. Prima is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.
Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.
For further information please contact:
Australian Investors/Media:
Mr Matthew Gregorowski,
+61 2 8234 0105; mgregorowski@citadelmagnus.com
Matthew Beck, The Trout Group LLC
+1 (646) 378-2933; mbeck@troutgroup.com